SeqOnce Biosciences Inc.

24 posts

SeqOnce Biosciences Inc. banner
SeqOnce Biosciences Inc.

SeqOnce Biosciences Inc.

@SeqOnceBio

SeqOnce BioSciences, Inc. is a privately held genomics tools company located in Carlsbad, CA. Focus areas include infectious disease, qPCR, NGS, and development

Calsbad, CA Katılım Nisan 2018
85 Takip Edilen68 Takipçiler
SeqOnce Biosciences Inc.
SeqOnce Biosciences Inc.@SeqOnceBio·
SeqOnce Biosciences - Expands Their Pathogen Assay Suite with the Addition of RT-qPCR Measles Panel News provided by SeqOnce Biosciences, Inc.  Jul 01, 2025, 10:30 ET CARLSBAD, Calif., July 1, 2025 /PRNewswire/ -- SeqOnce, a company focused on the research, development, and commercialization of qPCR and NGS genomics tools for the Infectious Disease Research & CLIA Testing Market, has launched their new Measles Panel A. "This expansion of our best-in-class RT-qPCR assays for our customers ensures that we can effectively partner throughout their pathogen analysis, from the earliest development stages to clinical research to screening patient samples, where working with multiplex qPCR kits is needed," says SeqOnce CEO Chris Angermayer. "We are committed to constantly improving and innovating our offerings to keep pace with the evolving field of Infectious Disease Research & CLIA Testing Market. Whatever we can do to help keep our environment and community safe by providing genomic tools for those who need them, we will do." SeqOnce's Measle Panel A was developed due to the increase in Measle cases in the United States. Measle Panel A is compatible with Bio-Rad, Roche and ABI qPCR systems. The assay has been specially formulated to detect the D8 genotype responsible for the recent outbreak in the United States but will also detect all know circulating viruses. "Our approach to product development involves talking to our customers about what they need based on trends in the marketplace.  Once we see a need we can solve, we get to work using our Bioinformatic tools to design the panels that work with our enzymes, fluorophores and buffers" says SeqOnce Chief Science Officer Joe Dunham. "Using this approach allows us to develop high quality products for our customers that use our other products as well. SeqOnce's product portfolio includes multiplex qPCR assay for Respiratory Diseases, Women's Health and Antibiotic Resistance. Please visit our website at seqonce.com to learn more. About SeqOnce, Inc. SeqOnce BioSciences, Inc. is a privately held genomics tools company located in Carlsbad, CA. Focus areas include infectious disease, qPCR, NGS, and development of novel technology platforms that are used for Research Only efforts. seqonce.com For SeqOnce Information Contact: Chris Angermayer at 1 (626)460-3050 SOURCE SeqOnce Biosciences, Inc.
English
0
0
0
25
SeqOnce Biosciences Inc.
SeqOnce Biosciences Inc.@SeqOnceBio·
SeqOnce Biosciences, Inc's Reg CF offering is available from Republic.  Please see our company presentation and visit Republic if interested in investing at the following link. republic.com/seqonce
English
0
0
1
35
SeqOnce Biosciences Inc.
SeqOnce Biosciences Inc.@SeqOnceBio·
NGS needs to be streamlined and simplified. Introducing SeqOnce and Done blog. We will highlight novel applications, describe useful parameter involved with #NGS, and comment on emerging and current technologies. Check in regularly to learn more bit.ly/2IhomDn
English
0
0
1
0
SeqOnce Biosciences Inc.
SeqOnce Biosciences Inc.@SeqOnceBio·
#ABRF 2019 was a great success... Catch the Rhino! RhinoSeq launch. Hanging with the SeqOnce team and friends.
SeqOnce Biosciences Inc. tweet mediaSeqOnce Biosciences Inc. tweet mediaSeqOnce Biosciences Inc. tweet media
English
2
0
6
0
SeqOnce Biosciences Inc. retweetledi
Veritas Genetics
Veritas Genetics@VeritasGenetics·
What's next in the #genomics revolution? @RodrigoATCG and @mcgenome define 'The Era of The Social Genome' where insights from your #DNA will be integrated into aspects of your everyday life. Check out the thought piece and let us know what you think! bit.ly/2XJrcWL
Veritas Genetics tweet media
English
0
7
10
0